Proton therapy for prostate cancer is advantageous to imrt according to new study

(Northwestern Memorial HealthCare) Proton therapy treatment for prostate cancer is associated with higher survival rates and decreased risk of complications compared to intensity-modulated radiation therapy (IMRT) according to a new study by researchers at the Northwestern Medicine Chicago Proton Center.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Discussion PSMA PET-CT imaging may have a substantial impact on clinical management in prostate cancer patients at the time of initial staging or with biochemical failure; yet this modality does not appear useful in the management of patients with known metastatic disease.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Discussion Our results demonstrated that Fluciclovine PET/CT detected more bone metastases than bone scan. Importantly, there were no lesions identified by bone scan that was missed by Fluciclovine PET/CT. With the extra capacity of detecting soft tissue metastasis in PET/CT, Fluciclovine PET/CT may render bone scan unnecessary to investigate metastatic prostate cancer.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Abstract Direct and absolute analysis of microRNAs (miRNAs) in complex media (e.g., human serum) is still a big challenge due to the issues with off-analyte absorption, low sensitivity and specificity. In this work, we have fabricated the erythrocyte membrane-biointerfaced spherical nucleic acids (EMSNAs) for miRNA assay, which not only enables tailor-engineered signal amplification but also exhibits anti-interference property. As a consequence, it is possible to achieve a single-step quantification of miRNAs in complex media without the process of enzymatic amplification, which can vastly simplify the detection p...
Source: Analytica Chimica Acta - Category: Chemistry Authors: Tags: Anal Chim Acta Source Type: research
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.9b00464
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
We report our institution's high-volume experience and the most mature data to date on outcomes with 131Cs prostate BT.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
AbstractMetastatic spine disease (MSD) is a severe event in cancer patients. Experimental data indicate that bone metastasis is mostly mediated by blood flow-dependent, passive arrest of circulating tumor cells to the bone metastatic niche (BMN). Here, we have set out to test these experimental observations in a clinical, human setting to improve our understanding of MSD. 507 patients, treated on spinal metastases in our institution from 2005 to  2015 were retrospectively evaluated. We identified 259 patients with accessible staging reports of the skeleton before and at initial diagnosis of MSD. Data analysis compri...
Source: Clinical and Experimental Metastasis - Category: Cancer & Oncology Source Type: research
Naim Prostate cancer (PCa) is one of the most common cancer types in men worldwide. Heat shock proteins (HSPs) are molecular chaperones that are widely implicated in the pathogenesis, diagnosis, prognosis, and treatment of many cancers. The role of HSPs in PCa is complex and their expression has been linked to the progression and aggressiveness of the tumor. Prominent chaperones, including HSP90 and HSP70, are involved in the folding and trafficking of critical cancer-related proteins. Other members of HSPs, including HSP27 and HSP60, have been considered as promising biomarkers, similar to prostate-specific membrane...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
British Journal of Cancer, Published online: 16 August 2019; doi:10.1038/s41416-019-0542-2Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 14 August 2019Source: European UrologyAuthor(s): Neil B. Desai, Kevin Courtney, Rathan M. Subramaniam, Jeffrey A. Cadeddu
Source: European Urology - Category: Urology & Nephrology Source Type: research
A federal appeals court affirmed the validity of Sanofi's first patent on prostate-cancer drug, Jevtana.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Intensity-Modulated Radiation Therapy | International Medicine & Public Health | Prostate Cancer | Proton Therapy | Radiation Therapy | Study